Comparative Analysis of PPIs vs. H2RAs in Gastrointestinal Therapy: Efficacy, Safety, and Cost

This review article provides an in-depth comparative analysis of Proton Pump Inhibitors (PPIs) and Histamine-2 Receptor Antagonists (H2RAs) in the treatment of gastrointestinal disorders, focusing on efficacy, safety, and economic considerations.PPIs and H2RAs are widely used to manage conditions such as gastroesophageal reflux disease (GERD), peptic ulcer disease, and Zollinger-Ellison syndrome.This article evaluates numerous clinical studies and meta-analyses to discern the therapeutic advantages and limitations of both drug classes.Efficacy is examined through clinical trial outcomes, highlighting PPIs' superior acid suppression and longer duration of action compared to H2RAs.PPIs are shown to provide more effective and sustained symptom relief, particularly in severe GERD and erosive esophagitis.Safety profiles are scrutinized, noting that while both drug classes are generally well-tolerated, PPIs are associated with increased risks of long-term adverse effects such as bone fractures, renal disease, and vitamin B12 deficiency.Conversely, H2RAs have a lower incidence of severe adverse effects but are less potent, potentially leading to incomplete symptom control in some patients.Economic aspects are also discussed, considering drug costs, long-term healthcare expenses, and the impact on quality of life.PPIs, despite being more expensive upfront, may reduce overall healthcare costs by decreasing the need for further medical interventions due to their higher efficacy.The review concludes with recommendations for clinical practice, advocating for a balanced approach that considers individual patient needs, potential risks, and cost-effectiveness, ensuring optimal therapeutic outcomes in gastrointestinal disorder management.